drugset / Trial / NCT00041327
Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Antiviral therapy may kill viruses such as HTLV-1 that can cause cancer. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with antiviral drugs and interferon alfa may be effective in treating adult T-cell leukemia/lymphoma. PURPOSE: Phase II trial to determine the effectiveness of combination chemotherapy followed by antiviral therapy and interferon alfa in treating patients who have adult T-cell leukemia/lymphoma caused by HTLV-1.
Timeline
- Start
- 2002-10
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 10 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Lamivudine | Other / unclassified | 150 mg | Oral |
| Subject | Prednisone | Other / unclassified | 60 mg/m2 | Oral |
| Subject | Vincristine | Small molecule | 0.4 mg/m2 | Intravenous |
| Subject | Zidovudine | Small molecule | 300 mg | Oral |
| Subject | interferon alfa-2b | Protein / enzyme biologic | 0.009 iu | Subcutaneous |
| Background | filgrastim | Protein / enzyme biologic | 5 ug/kg | Subcutaneous |